A number of drugs has in the last years been approved by the FDA for use on MDS patients. Not all these drugs are approved in all countries. As of the middle of 2011 the following drugs have been approved by the FDA for treatment in certain MDS patient subgroups:
- Dacogen (Decitabine) Initial approval May 2nd, 2006 and ammended March 11th, 2010. All patients with MDS. This drug is manufactured by EIsai.
- Revlimid (Lenalidomide) Initial approval December 27th, 2005 and latest ammenment October 12th, 2010. Only for patients with delition 5q MDS. This drug is manufactured by Celgene.
- Vidaza (Azacitidine) Initial approval May19th, 2004 and latest ammenment August 20th, 2008. For patients with FAB-subtypes RA, RARS, and RAEB. This drug is manufactured by Celgene.